CTOs on the Move


 
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.89bio.com
  • 535 Mission Street 14th Floor
    San Francisco, CA USA 94105
  • Phone: 212.520.2765

Executives

Name Title Contact Details

Funding

89bio raised $60M on 10/25/2018
89bio raised $83.8M on 07/14/2020

Similar Companies

InVitria

InVitria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirna Therapeutics

Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

The Coding Source LLC

The Coding Source LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.

DEKA Research and Development Corporation

DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.